ImmVirX has used one of the world’s largest cancer research stages to sharpen its pitch that oncolytic RNA immunotherapies could materially shift outcomes in some of the most difficult-to-treat tumours.
At the American Association for Cancer Research annual meeting in 2026, the company reported new Phase 1b clinical data for its lead candidate IVX037 while also outlining broad preclinical activity for its second asset, IVX055, reinforcing a platform strategy built on receptor-targeted viral therapies.
The clinical update centres on an ongoing open-label, multicentre study evaluating IVX037, administered directly into tumours, in combination with a PD1 inhibitor in patients with advanced microsatellite-stable colorectal, gastroesophageal, and ovarian cancers. These tumour types are typically resistant to checkpoint inhibitors alone, underscoring their persistent unmet need.
>Early findings point to a therapy that is both active and tolerable. Multiple intratumoural doses have been delivered without dose-limiting toxicities and with no grade 3 or higher treatment-related adverse events reported to date. The safety profile is critical given the combination approach, where IVX037 is intended to prime tumours and enhance responsiveness to immunotherapy.
Preliminary signals of efficacy are beginning to emerge. In earlier Phase 1a data, a patient with advanced colorectal cancer achieved a biopsy-confirmed complete response following treatment, with no new metastatic disease observed for almost two years without additional therapy. Other patients have demonstrated reductions in tumour lesions alongside decreases in biomarkers such as CEA, suggesting a biological effect consistent with anti-tumour activity.
Investigators involved in the study have pointed to these outcomes as meaningful in a setting where long-term survival is typically low, describing the early signals as encouraging and supportive of continued development.
The mechanism underpinning IVX037 reflects a broader shift in oncology towards combination immunotherapy strategies. The therapy is designed as a receptor-targeted oncolytic RNA virus that selectively infects and destroys cancer cells while simultaneously triggering immune activation within the tumour microenvironment. This dual action is intended to convert immunologically 'cold' tumours into ones that are more responsive to checkpoint inhibition.
Alongside the clinical update, ImmVirX used the AACR forum to highlight the emerging profile of IVX055, its second pipeline candidate. Preclinical data indicate potent anti-tumour activity across multiple cancer types, supporting plans to advance the therapy into human studies and expand the company’s combination immunotherapy approach.
Both assets are part of a broader effort to target some of the most prevalent and challenging cancers, including colorectal, gastric, liver and ovarian malignancies, where current treatment options remain limited. The company’s strategy is explicitly focused on enhancing the effectiveness of existing modalities such as checkpoint inhibitors and CAR T therapies rather than competing directly with them.
The progression of IVX037 into later-stage combination cohorts and the anticipated clinical entry of IVX055 mark a transition point for the platform. While still early, the convergence of safety, biological activity and a clear mechanistic rationale positions ImmVirX within a resurgent field of oncolytic virus therapies that is again attracting industry and investor attention.